Complete Your CE Test Online - Click Here to other professionals or members of a pain management team. Some clinicians may be willing and able to continue a regimen of opioid therapy even after the discovery of aberrant behavior if done with intensified monitoring, patient counseling, and careful documentation of all directives. This level of vigilance and risk management, however, may exceed the abilities and resources of the average prescriber. In such cases, referral to a provider with specialized skills or experience in dealing with high-risk patients may be prudent. Patient education about controlled substances Responsible prescribing of controlled substances requires clinicians to fully educate patients about the many issues related to safe use, storage, and disposal of such substances due to their potential for misuse or abuse. Not only will educating patients possibly improve their adherence to the medication regimen, it may prevent accidental overdose or inadvertent diversion to non-authorized users. Education about safe use, storage, and disposal should be part of every provider-patient interaction involving these substances. This education may include verbal instructions delivered by a prescriber, nurse or other trained clinic staff person, written handouts, guidance through other media (such as CD, DVD, or the Internet), or referral to other resources (such as a local clinic webpage or national resources). Patients should be instructed about the proper use and administration of any prescribed controlled substances, including special directions about timing of doses, whether to administer the medication with or without food, and any foods or other medications to avoid while administering [33]. Here are some other key ideas to convey to patients about proper use: ● ● Read the prescription container label each time to check dosage. ● ● Never use medicines after the expiration date. ● ● Never share medicines with others. ● ● Do not take medication with alcohol or other sedatives. ● ● Do not take a medicine to promote sleep (unless it has been specifically prescribed for that use). ● ● Never break, chew, or crush medicines. ● ● Transdermal products may be affected by external heat, fever, and exertion, which can increase absorption of a medication, leading to a potentially fatal overdose. In addition, transdermal products with metal foil backings are not safe for use in MRI scanners. Patients should be continually reminded that sharing, selling, or giving away opioids is against the law and poses significant hazards not just to the recipient of the medications, but also to society at large. Physicians must also educate patients about the importance of proper storage of controlled substances. It is best if all controlled substances are stored in a locked cabinet or other secure storage unit. Storage areas should be cool, dry, and out of direct sunlight. Remind patients not to store medications in their car, to keep medications in the original containers, and to avoid storing medications in the refrigerator or freezer unless specifically directed to do so by a health care provider or pharmacist. Patients, family members, or caregivers should also monitor pill containers so they will know if any pills are missing. Proper disposal of unused controlled substances is also important. Instruct patients to follow the instructions of a pharmacist for disposal or to mix the medicines with an undesirable substance, such as used coffee grounds or cat litter, put the mixture into a disposable container with a lid or a sealable bag, and place it in the trash. The DEA also sponsors the National Take Back Initiative, which coordinates periodic controlled substance take-back programs at thousands of state and local law enforcement agencies across the country. More information about these programs can be found at: http://www.deadiversion.usdoj.gov/ drug_disposal/takeback/index.html Nursing consideration: Nurses are often the healthcare professionals who provide the most detailed patient/family education. They must be current in knowledge of drug abuse and make sure that the patient/ family education they provide is accurate. They must also assess patient/family knowledge acquisition of all facets of education. Conclusion Clearly, the rise of prescription drug abuse, and the wider use of controlled substances, is related to social, cultural, and economic forces both larger and more powerful than any role that clinicians have in their day-to-day work with controlled substances [35]. But, clinicians can take simple steps to insure that controlled substances are prescribed safely and transparently. By doing so, clinicians can protect not only their patients, but also society at large and themselves, should they encounter the scrutiny of regulators. References 1. Berland, D., & Rodgers, P. (2012). Rational use of opioids for management of chronic nonterminal pain. American Family Physician, 86(3), 252–258. 2. Ault, A. (2015). CDC opioid guideline lands, controversy continues. Retrieved from http://www. medscape.com/viewarticle/856203 3. National Institute on Drug Abuse. (2014). Testimony to Congress: America’s addiction to opioids: Heroin and prescription drug abuse. Retrieved from http://www.drugabuse.gov/about-nida/legislative- activities/testimony-to-congress/2015/americas-addiction-to-opioids-heroin-prescription-drug-abuse - _ftn5http://www.drugabuse 4. American Society of Addiction Medicine Opioid Addiction Disease. (2015). Fact sheet. Retrieved fromhttp://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf 5. Centers for Disease Control and Prevention. (2016). Injury prevention and control: Opioid overdose. Prescription opioid overdose data. Retrieved from http://www.cdc.gov/drugoverdose/data/overdose. html 6. Hahn, K. L. (2011). Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs. American Health Drug Benefits, 4(2), 107–114. PMCID: PMC4106581. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106581/pdf/ahdb-04-107.pdf 7. ER/LA Opioid Analgesics REMS. (2016). Risk evaluation and mitigation strategy (REMS). Retrieved fromhttp://www.er-la-opioidrems.com/IwgUI/rems/home.action 8. WebMD. (2016). What is chronic pain? Retrieved fromhttp://www.webmd.com/pain-management/ guide/understanding-pain-management-chronic-pain http://www.webmd.co 9. World Health Organization. (2016). Pharmacovigilance. Retrieved from http://www.who.int/ medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/ 10. Centers for Disease Control. (2016). CDC guideline for prescribing opioids for chronic pain. Retrieved from https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htmhttps://www.cdc.gov/ 11. OSCE Skills. (2016). History taking. Retrieved from http://www.osceskills.com/e-learning/subjects/ patient-history-taking/http://www.osceskill 12. Goodwin J., & Bajwa Z. H. (2004). Evaluating the patient with chronic pain. In C. A. Warfield & Z. H. Bajwa (Eds.), Principles and practice of pain medicine (2nd ed.) New York: McGraw-Hill Companies, Inc. 13. Oklahoma, Physician Advisory Committee. (2007). Guidelines for prescription of opioid medications for acute and chronic pain. Retrieved from http://www.owcc.state.ok.us/PDF/Guidelines for the Prescription of Opioid Medications rev 11-01-07 COMPLETE.pdf 14. Coombs, R. B., Jarry, J. L., Santhiapillai, A. C., et al. (1996). The SISAP: A new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain within general medical practice. Pain Research and Management, 1(3), 155–162. 15. Webster, L. R., & Dove, B. (2007). Avoiding opioid abuse while managing pain. North Branch, MN: Sunshine River Press. 16. Chou, R., Fanciullo, G. J., Fine, P. G., et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain 10(2), 113–130. doi:10.1016/j. jpain.2008.10.008 17. Google Image. (2016). Retrieved from https://understandingpain.wordpress.com/category/pain- assessment-tools/ 18. Google Image. (2016). Retrieved from http://www.gridgit.com/post_pain-rating-chart_10266/ 19. Hawker, G. A., Mian, S., Kenzerska, T., et al. (2011). Measures of adult pain: Visual analog scale for pain (VAS Pain), numeric rating scale for pain (NRS Pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care & Research, 63, Issue Supplement S11, S240–S252. doi: 10.1002/acr.20543 20. Washington State Department of Social and Health Services. (2016). Best practices: Summary checklist tools for documenting medical necessity in clinical notes when prescribing opioids. Retrieved from http://www.hca.wa.gov/medicaid/pharmacy/Documents/best_practices_summary_ checklist.pdf 21. Kraus, C. N., Baldwin, A. T., Curro, F. A., et al. (2015). Clinical implications of patient-provider agreements in opioid prescribing. Current Drug Safety, 10(2), 159–164. 22. Cheatle, M. D., & Savage, S. R. (2012). Informed consent in opioid therapy: A potential obligation and opportunity. Journal of Pain and Symptom Management, 44(1), 105–116. doi: 10.1016/j. jpainsymman.2011.06.015 23. Indian Health Service. (2016). Function-based objectives. Retrieved from http://www.ihs.gov/ painmanagement/treatmentplanning/functionbasedobjectives/http://www.ihs.gov/p 24. Fishman, M. D., & Scott, M. (2007). Responsible opioid prescribing: A Physician’s Guide (pp. 34–42). Washington, DC: Waterford Life Sciences. 25. Michigan State University College of Human Medicine. (2008). Pain relief for terminally ill patients. Retrieved from http://learn.chm.msu.edu/painmanagement/chooseopioid.asp 26. GlobalRPh. (2016). Pain management, opiates. Retrieved from http://www.globalrph.com/pain.htm 27. U.S. Food and Drug Administration. (2014). Acetaminophen prescription combination drug products with more than 325 mg: FDA statement-recommendation to discontinue prescribing and dispensing. Retrieved from http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm381650.htm 28. Brennan, M. J. (2013). Update on prescription extended-release opioids and appropriate patient selection. Journal of Multidisciplinary Healthcare, 6, 265–280. doi: 10.2147/JMDH.S38562 29. U.S. Food and Drug Administration. (2015). Risk evaluation and mitigation strategy (REMS) for extended-release and long-acting opioids. Retrieved from http://www.fda.gov/Drugs/DrugSafety/ InformationbyDrugClass/ucm163647.htmhttp://www.fda.gov/D 30. Bolen, J. D. (2015). Treating patients with ER/LA opioid analgesics: Initiating, modifying, and discontinuing therapy. Emerging Solutions in Pain. Retrieved from http://www. emergingsolutionsinpain.com/rems-resources/927-treating-patients-with-er-la-opioid-analgesics- initiating-modifying-and-discontinuing-therapy 31. Fraserhealth. (2006). Principles of opioid management. Retrieved from https://www.fraserhealth.ca/ media/16FHSymptomGuidelinesOpioid.pdf 32. McCaffery, M., Ferrell, B. R., & Pasero, C. (2000). Nurses’ personal opinions about patients’ pain and their effect on recorded assessments and titration of opioid doses. Pain Management Nursing, 1(3), 79–87. Retrieved from http://www.painmanagementnursing.org/article/S1524-9042(00)53232-9/ abstract nursing.elitecme.com Page 7